BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zemocimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zemocimig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07416526-11331@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416526)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Factor VIII Prophylaxis in Participants With 
 Hemophilia A\nEstimated primary completion: 23 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07416526
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416604-11331@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07416604)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: A Clinical Study to Evaluate the E
 ffects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophi
 lia A\nEstimated primary completion: 29 February 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zemocimig#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07416604
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838194-11331@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zemocimig: Phase 3 readout est. (NCT07838194)
DESCRIPTION:Zemocimig\, phase 3.\nStudy: Clinical Trial of NXT007 for the P
 rophylactic Treatment of Hemophilia A in Infants and Children\nEstimated p
 rimary completion: 30 September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zemocimig#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07838194
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987449-11331@assetmemo.bio
DTSTAMP:20261121T004508Z
DTSTART;VALUE=DATE:20331211
DTEND;VALUE=DATE:20331212
SUMMARY:Zemocimig: Phase 1/2 readout est. (NCT05987449)
DESCRIPTION:Zemocimig\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, Pharmacokinetics\, Pharmacodynamics\, and Efficacy of NXT0
 07 in Persons With Severe or Moderate Hemophilia A\nEstimated primary comp
 letion: 11 December 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zemocimig#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05987449
URL:https://assetmemo.bio/drug/zemocimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
